Table 5.
Summary of data obtained in the present study and other studies.
| Study/patient (n) | Our study (43) | Young TK, et al.11 (35) | Kaushik S, et al.12 (33) | Riollano-Cruz M, et al.14 (15) | Feldstein LR, et al. (186)2 | Torres JP, et al.5 (27) | Jonat B, et al.7 (54) | Yuksel S, et al.13 (17) |
|---|---|---|---|---|---|---|---|---|
| Retro/prospective (R/P) | P | R | R | R | R + P | R + P | R + P | P |
| Age, years median | 7.5 (0.5‒15) | 2 (0.2‒17) | 10 (6‒13) | 12 (3‒20) | 8.3 (3.3‒12.5) | 6 (0‒14) | 7 (0.8‒20) | 8 (3.5‒13.5) |
| Gender, male, n (%) | 25 (58.1) | 19 (54) | 20 (61) | 11 (73) | 115 (62) | 14 (52) | 25 (46) | 7 (41.1) |
| Systemic symptoms | ||||||||
| Mucocutaneous symptoms, n (%) | 40 (93) | 29 (83) | 7 (21) | NR | 137 (74) | NR | NR | NS |
| Gastrointestinal symptoms, n (%) | 29 (67.4) | 31 (88.6) | NS | 13 (87) | 171 (92) | NS | 45 (83) | 13 (76.5) |
| Cardiovascular symptoms, n (%) | 20 (46.5) | 19 (54.3) | 21 (63) | 13 (87) | 149 (80) | NR | NS | NR |
| Respiratory symptoms, n (%) | 13 (30.2) | NS | NS | NR | 131 (70) | NS | 12 (22) | 3 (17.6) |
| Neurologic symptoms, n (%) | 6 (14) | NR | 4 (12) | NR | NS | NR | 22 (41) | 3 (17.6) |
| Cutaneous rash, n (%) | 35 (81.4) | 28 (80) | 14(42) | 7 (47) | 110 (59) | 14(52) | 41 (76) | NS |
| Urticarial lesions, n (%) | 21 (48.8) | 3 (9) | NR | NR | NR | NR | NR | NS |
| Maculopapular, n (%) | 11 (25.6) | NR | NR | NR | NR | NR | NR | 7(41.2) |
| Livedoid, n (%) | 5 (11.6) | NR | NR | NR | NR | NR | NR | NR |
| Pseudopernio, n (%) | 1 (2.3) | NR | NR | NR | NR | NR | NR | NR |
| Oral mucosal changes, n (%) | 28 (65.1) | 20 (57) | 7 (21) | NR | 78 (42) | 11 (41) | NS | 0 |
| Fissured lips, n (%) | 12 (27.9) | NR | NR | NR | NR | NR | NR | NR |
| Cheilitis, n (%) | 10 (23.3) | NR | NR | NR | NR | NR | NR | NR |
| Diffuse hyperemia of the oral mucosa, n (%) | 8 (18.6) | NR | NR | NR | NR | NR | NR | NR |
| Strawberry tongue, n (%) | 6 (13.9) | 8 (23) | NR | NR | NR | NR | NR | NR |
| Herpes labialis, n (%) | 3 (6.9) | NR | NR | NR | NR | NR | NR | 0 |
| Genital erosion, n (%) | 0 | NR | NR | NR | NR | NR | NR | 0 |
| Eye involvement, n (%) | 28 (65.1) | NS | NR | NR | NR | NR | NR | NR |
| Conjunctival injection, n (%) | 25 (58.1) | 21 (60) | 12 (36) | 4 (27) | 103 (55) | 13 (48) | 31 (57) | 9 (52.9) |
| Periorbital edema, n (%) | 4 (9.3) | 7 (20) | NR | NR | NR | NR | NR | NR |
| Symmetrical edema of the hands and feet, n (%) | 4 (9.3) | 14 (40) | NR | 4 (27) | NS | NR | NR | NR |
| Periungual desquamation, n (%) | 2 (4.7) | NR | NR | NR | NR | NR | NR | NR |
NR, Non-Reported; NS, Non-Specified.